Impairment of the Retinal Endothelial Cell Barrier Induced by Long-Term Treatment with VEGF-A165 No Longer Depends on the Growth Factor’s Presence
Heidrun L. Deissler(Universität Ulm), Armin Wolf(University Hospital Ulm)
Cited by 5
Related Papers
Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study
|American Journal of Ophthalmology|2016|89
Faricimab Reverts VEGF-A165-Induced Impairment of the Barrier Formed by Retinal Endothelial Cells
|International Journal of Molecular Sciences|2025|1